Literature DB >> 10837445

Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals.

O Chesneau1, A Morvan, N E Solh.   

Abstract

Twenty-five different Staphylococcus aureus strains that are widespread in France were screened by various methods for heterogeneous and low-level resistance to vancomycin. Population analysis on brain-heart infusion agar containing 4 mg/L of the drug detected resistant cells at frequencies of 10-7 to 10-6 in five multiply resistant strains. There was no antagonism between vancomycin and beta-lactam antibiotics. One of the five strains, isolated in 1993, was considered a putative progenitor of a French nosocomial S. aureus strain isolated in 1998 and for which the vancomycin MIC was 8 mg/L.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837445     DOI: 10.1093/jac/45.6.887

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  22 in total

1.  Staphylococcus heterogeneously resistant to vancomycin in China and antimicrobial activities of imipenem and vancomycin in combination against it.

Authors:  Wu Benquan; Tang Yingchun; Zhang Kouxing; Zhang Tiantuo; Zhu Jiaxing; Tan Shuqing
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Clonal diversity among streptogramin A-resistant Staphylococcus aureus isolates collected in French hospitals.

Authors:  Julien Haroche; Anne Morvan; Marilyne Davi; Jeanine Allignet; François Bimet; Névine El Solh
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

3.  Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.

Authors:  B Edwards; K Milne; T Lawes; I Cook; A Robb; I M Gould
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

4.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

5.  Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.

Authors:  K Riederer; S Shemes; P Chase; A Musta; A Mar; R Khatib
Journal:  J Clin Microbiol       Date:  2011-04-13       Impact factor: 5.948

6.  Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Akira Iwamoto; Jian-Qi Lian; Hui-min Neoh; Toshiki Maruyama; Yataro Horikawa; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 7.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

8.  First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.

Authors:  S Trakulsomboon; S Danchaivijitr; Y Rongrungruang; C Dhiraputra; W Susaemgrat; T Ito; K Hiramatsu
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

9.  Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.

Authors:  Miki Matsuo; Longzhu Cui; Jeeyoung Kim; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

10.  DNA macroarray for identification and typing of Staphylococcus aureus isolates.

Authors:  Salim Trad; Jeanine Allignet; Lionel Frangeul; Marilyne Davi; Massimo Vergassola; Elisabeth Couve; Anne Morvan; Amel Kechrid; Carmen Buchrieser; Philippe Glaser; Névine El-Solh
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.